Avastin Receives Positive Opinion in Europe for First-Line Treatment of Advanced Kidney Cancer Patie

"The AVOREN study has shown us that Avastin is an effective and safe treatment for patients with kidney cancer," said Professor Bernard Escudier, Head of Immunotherapy and Innovative Therapy Unit, Institut Gustave-Roussy, Paris, France and Principal Investigator of the pivotal AVOREN study. "This announcement is very significant because this drug offers new therapeutic options in advanced kidney cancer, where chemotherapy and radiotherapy are not as effective as in other cancers."
On an annual basis, in excess of 200,000 people worldwide will receive a diagnosis of kidney cancer and more than 100,000 people worldwide will lose their lives to the disease(i). These figures can be expected to increase as the number of people suffering from cancer in general rises by 50%, as recently estimated by the WHO(ii).